Acetyl Tetrapeptide-3 Peptide

Clinical data indicates over 90% of adult hair loss cases are androgenetic alopecia. Its core pathogenesis lies in scalp 5α-reductase catalyzing testosterone conversion into dihydrotestosterone (DHT). High-concentration DHT binds to follicle receptors, continuously damaging dermal papilla cells and forcing healthy thick terminal hair follicles to gradually atrophy into fine vellus hair roots, eventually leading to pilosebaceous unit closure and permanent alopecia.

Unlike conventional anti-hair loss ingredients that directly inhibit 5α-reductase, acetyl tetrapeptide-3 peptide does not participate in human androgen metabolism regulation and causes no endocrine disorders. Instead, it targets downstream pilosebaceous unit signaling pathways to enhance follicular cell tolerance to DHT damage.

Scalp micro-inflammation is an easily overlooked cause of hair loss. Impaired scalp barrier, Malassezia overproliferation, and external irritants trigger accumulation of inflammatory factors such as interleukin-6 (IL-6) and TNF-α, which continuously erode the follicular basement membrane, loosen hair anchoring structures, and induce diffuse hair shedding.

Acetyl Tetrapeptide-3 exerts mild scalp anti-inflammatory activity by regulating inflammatory signaling pathways in scalp keratinocytes, lowering pro-inflammatory factor release and repairing damaged scalp barriers. Compared with irritating anti-inflammatory ingredients like salicylic acid and ketoconazole, this peptide does not cause scalp dryness or stinging and can be used long-term on fragile sensitive scalps.

Double-blind human trial results demonstrate that for subjects with scalp redness, excessive sebum, itching and hair shedding, continuous use of scalp essence containing 0.1% Acetyl Tetrapeptide-3 for 4 weeks reduces scalp inflammation scores by 38% and cuts hair loss during daily combing and shampooing by 42%, effectively ameliorating inflammation-induced telogen effluvium.

Extend Anagen Phase & Shorten Telogen Duration

Normal human hair growth is divided into anagen, catagen and telogen phases. Healthy individuals have approximately 67% of follicles in the anagen phase, while alopecia sufferers experience drastically shortened anagen phases, with massive pilosebaceous units prematurely entering telogen, resulting in insufficient new hair growth and sparse overall hair volume.

Acetyl tetrapeptide-3 peptide rebalances pilosebaceous unit growth rhythms by regulating key signaling proteins governing follicle cycles and inhibiting follicle transition from anagen to catagen. Research published in authoritative dermatology journals verifies that peptide intervention elevates the proportion of scalp follicles in the anagen phase to 82%, greatly prolonging healthy hair growth cycles, delaying natural hair shedding, and lowering follicle dormancy probability to prevent mass shedding caused by synchronized telogen entry of large follicle areas.

Poor scalp microcirculation and insufficient follicular nutrient supply are major triggers of pilosebaceous unit dormancy and fine hair. Acetyl Tetrapeptide-3 gently boosts superficial scalp microcirculation, accelerates delivery of blood-borne nutrients to the scalp, and supplies essential growth nutrients (amino acids, oxygen) to dermal papilla cells, improving dry, fine and slow-growing hair induced by insufficient scalp blood supply.

Unlike cooling circulation-promoting ingredients such as menthol, this peptide does not trigger drastic dilation of scalp blood vessels, delivering mild and long-lasting effects suitable for long-term scalp and pilosebaceous unit maintenance.Overall, Acetyl Tetrapeptide-3 forms an integrated three-in-one functional system of anti-hair loss, hair fixation and hair regrowth: it blocks alopecia triggers to reduce shedding in the early stage, reinforces hair roots to stabilize existing strands in the middle stage, and activates follicles to generate new hair in the late stage, fully covering full-cycle scalp care demands for alopecia.